These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31301319)

  • 1. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
    Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
    Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
    Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
    Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
    Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
    Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response.
    Shi P; Zha J; Feng J; Jiang Z; Zhao H; Deng M; Liao N; Li P; Jiang Y; Song H; Xu B
    Stem Cell Rev Rep; 2021 Apr; 17(2):616-627. PubMed ID: 33078278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase.
    Wang W; Jiang Z; Wang L; Wang A; Liu J; Chen C; Yu K; Zou F; Wang W; Liu J; Liu Q
    Cancer Lett; 2020 Mar; 473():130-138. PubMed ID: 31904486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
    Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
    J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
    Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
    Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 15. Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells.
    Wang R; Li Y; Gong P; Gabrilove J; Waxman S; Jing Y
    Mol Cancer Ther; 2018 Sep; 17(9):1871-1880. PubMed ID: 29959200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
    Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
    Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
    Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
    Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML.
    Guo D; Zhao Y; Wang N; You N; Zhu W; Zhang P; Ren Q; Yin J; Cheng T; Ma X
    Blood; 2021 Aug; 138(6):464-479. PubMed ID: 33945602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.